Company Alphamab Oncology

Equities

9966

KYG0330A1013

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Alphamab Oncology

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 09:08:13 24/06/2024 BST			5-day change	1st Jan Change
2.41 ^HKD	-6.59%		-7.66%	-63.70%

06-05	ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment	MT
06-05	Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates	MT

Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The Company has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The Company operates its businesses in both domestic and overseas markets.

Number of employees: 435

HKD in Million	2022	Weight	2023	Weight	Delta
Biologics of Oncology 100.0 %	194	100.0 %	242	100.0 %	+24.60%

HKD in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	194	100.0 %	242	100.0 %	+24.60%

Managers	Title	Age	Since
Ting Xu CEO	Chief Executive Officer	51	31/10/08
Jing Han CMP	Compliance Officer	51	01/11/21
Jinbo Wang CTO	Chief Tech/Sci/R&D Officer	50	18/03/18
Liang Kong CTO	Chief Tech/Sci/R&D Officer	44	31/05/18
Lu Amy Sun CTO	Chief Tech/Sci/R&D Officer	67	31/05/19
Yang Liu COO	Chief Operating Officer	52	30/09/18
Jin Nan Wang IRC	Investor Relations Contact	42	-
Shaowei Yang PRN	Corporate Officer/Principal	48	12/06/17
Mike Liu PRN	Corporate Officer/Principal	58	30/04/18
Lok Yee Chan SEC	Corporate Secretary	35	-

Members of the board	Title	Age	Since
Cheng Wei BRD	Director/Board Member	56	23/11/19
Ting Xu CEO	Chief Executive Officer	51	31/10/08
Yang Liu COO	Chief Operating Officer	52	30/09/18
Dong Wu BRD	Director/Board Member	54	23/11/19
Zijian Guo BRD	Director/Board Member	63	26/08/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	964,923,807	474,870,857 ( 49.21 %)	0	49.21 %

Name	Equities	%	Valuation
Ting Xu 33.01 %	318,552,950	33.01 %	103 M $
Chuan Xiao Xue 8.887 %	85,750,000	8.887 %	28 M $
Xi Tian Zhang 8.887 %	85,750,000	8.887 %	28 M $
Advantech Advisors (HK) Limited 4.860 %	46,897,190	4.860 %	15 M $
Zhong Ou Asset Management Co., Ltd 1.660 %	16,019,563	1.660 %	5 M $
GF Fund Management Co., Ltd. 1.238 %	11,946,000	1.238 %	4 M $
First Seafront Fund Management Co., Ltd. 0.8828 %	8,518,000	0.8828 %	3 M $
Bosera Asset Management Co., Ltd. 0.3432 %	3,312,000	0.3432 %	1 M $
China Asset Management Co., Ltd. 0.2271 %	2,191,000	0.2271 %	711 352 $
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt) 0.1220 %	1,177,000	0.1220 %	382 137 $

Alphamab Oncology

175 Fangzhou Road Suzhou Industrial Park

215127, Suzhou

http://www.alphamabonc.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.4 CNY

Average target price

4.095 CNY

Spread / Average Target

+70.60%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALPHAMAB ONCOLOGY	-63.70%	319M
MODERNA, INC.	+34.14%	51.12B
IQVIA HOLDINGS INC.	-6.54%	39.4B
LONZA GROUP AG	+36.05%	38.48B
ICON PUBLIC LIMITED COMPANY	+12.62%	26.36B
CELLTRION, INC.	-12.11%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-13.43%	20.96B
UNITED THERAPEUTICS CORPORATION	+43.73%	14.02B
MEDPACE HOLDINGS, INC.	+31.81%	12.49B
BIO-TECHNE CORPORATION	-4.54%	11.61B

Other Biotechnology & Medical Research